Shinpoong Pharmaceutical

신풍제약 · 019170

Health Care Pharmaceuticals · KOSPI

Small-cap

Market cap US$347.9M (₩480.2B)

Overview

Shinpoong Pharmaceutical makes prescription and over-the-counter medicines supplied to patients and healthcare providers.

Listed on KOSPI, South Korea's main stock exchange, it operates as a mid-sized pharmaceutical company, too large to qualify as a small enterprise under Korean classification but below the largest tier. The company operates through a parent entity supported by six unlisted subsidiaries consolidated into its financial reporting.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$170.1M

▲ +6.2% YoY

Operating profit · FY2025

US$10.3M

Turned profitable

Net income · FY2025

US$6.1M

Turned profitable

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$145.1M(₩200.2B)	US$160.2M(₩221.1B)	US$170.1M(₩234.7B)
Operating profit	−US$34.3M(−₩47.4B)	−US$14.8M(−₩20.5B)	US$10.3M(₩14.3B)
Net income	−US$41.5M(−₩57.3B)	−US$11.1M(−₩15.4B)	US$6.1M(₩8.4B)

Revenue

FY2023US$145.1M
FY2024US$160.2M
FY2025US$170.1M

Operating profit

FY2023−US$34.3M
FY2024−US$14.8M
FY2025US$10.3M

Net income

FY2023−US$41.5M
FY2024−US$11.1M
FY2025US$6.1M

Key ratios (FY2025)

ROE

3.1%

Debt/Eq

30.2%

Op. margin

6.1%

Net margin

3.6%

Rev. YoY

▲ +6.2%

Why it matters

Shinpoong Pharmaceutical consolidates six unlisted subsidiaries into its group accounts, a structure common among mid-tier Korean pharmaceutical companies listed on KOSPI.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?